Clinical Trial Update: Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML [Phase 3]

View source ↗

Summary

Phase 3 continuation study of azacitidine with or without glasdegib in untreated AML, MDS, or CMML; trial completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelomonocytic Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Glasdegib (glasdegib)

Snippet

Sponsor: Pfizer | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 3 | Status: COMPLETED | Results posted: 2023-12-18